Edwards Lifesciences (EW) Total Non-Current Liabilities (2009 - 2026)

Edwards Lifesciences' Total Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $2.4 billion for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 1.41% year-over-year to $2.4 billion; the TTM figure through Mar 2026 stood at $2.4 billion (down 1.41% YoY), while the FY2025 annual figure was $2.9 billion, up 9.08% from the prior year.
• Total Non-Current Liabilities was $2.4 billion for Q1 2026 at Edwards Lifesciences, down from $2.9 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $3.0 billion in Q3 2024 to a low of $2.1 billion in Q3 2022.
• Historically, Total Non-Current Liabilities has averaged $2.5 billion across 5 years, with a median of $2.4 billion in 2026.
• The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities retreated 16.31% in 2022, then gained 25.41% in 2024.
• A 5-year view of Total Non-Current Liabilities shows it stood at $2.2 billion in 2022, then gained by 19.18% to $2.6 billion in 2023, then slipped by 0.93% to $2.6 billion in 2024, then grew by 9.08% to $2.9 billion in 2025, then decreased by 14.65% to $2.4 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $2.4 billion (Q1 2026), $2.9 billion (Q4 2025), and $2.6 billion (Q3 2025), per Business Quant data.